Merck

© Getty Images

Merck's path toward pharmacovigilance transformation

By Isabel Cameron

At Veeva R&D and Quality Summit 2023, Bio Pharma Reporter caught up with Courtney Gilbert, senior director, business system management and innovation, PV operations and global process enablement, at Merck.

Pic:getty/aydinmutlu

Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda

By Rachel Arthur

An mRNA cancer vaccine, in combination with Keytruda, reduced the risk of recurrence or death in melanoma patients by 44% compared to Keytruda alone, according to Phase 2b data. Merck and Moderna plan to initiate a Phase 3 study in the coming months.

Pic:getty/gilnature

Merck to acquire Prometheus Biosciences for $10.8bn

By Rachel Arthur

Merck will acquire Prometheus Biosciences, a San Diego biotech working on a precision medicine approach for developing therapeutics for the treatment of immune-mediated diseases.

Pic:getty/kojofeja

BigHat Biosciences enters AI research collaboration with Merck

By Rachel Arthur

BigHat Biosciences, a US biotech with a machine learning-guided antibody discovery and development platform, has announced a collaboration with Merck to apply its technology to design candidates for up to three drug discovery programs.

Pic:getty/courtneyk

Merck picks up another ADC agreement

By Ben Hargreaves

With speculation that Merck is lining up a multi-billion dollar acquisition in the ADC space, the company has agreed a second collaboration deal with Sichuan Kelun Pharmaceutical.

Pic:getty/jonathankitchen

Merck Q1: Keytruda sales up 23%

By Rachel Arthur

Merck’s cancer drug Keytruda continues to grow: helping Merck record ‘robust top-line and bottom-line growth’ across the company in Q1 2022.

Pic:getty/vladimirvladimirov

HPV vaccines reduce cervical cancer by 87%: study

By Rachel Arthur

Human papillomavirus (HPV) vaccines reduce cervical cancer rates by 87% in women who were offered the jab between the ages of 12-13, according to a study which analysed data from England's HPV vaccine program.

© GettyImages/Pheelings Media

FDA rebuff for Keytruda in breast cancer indication

By Jane Byrne

A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the company’s application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.

Pic:getty/mikemareen

Merck to help manufacture J&J COVID-19 vaccine

By Rachel Arthur

Merck’s US facilities will help manufacture Johnson & Johnson’s COVID-19 vaccine: which a $268.8m injection from the US government helping it adapt existing facilities for COVID-19 vaccines and medicines.

(Image: Getty/Golubovy)

Top five stories from September

By Ben Hargreaves

The news most interesting to our readers were those featuring collaborations, whether in the production of an Ebola vaccine, biosimilars entering new markets or creating new manufacturing modalities.